The best way to manage castrate-resistant prostate cancer (CRPC)
A hormone-resistant form of prostate cancer, also known as a hormone-refractory prostate cancer, grows when testosterone levels fall below or reach the castrate level. Blood test reports showing an increase in PSA (prostate-specific antigen) levels while testosterone levels are low will be used to determine whether you have castrate-resistant prostate cancer. Doctors will be able to plan your treatment procedure based on your PSA doubling time and imaging tests.
Prostate cancer with castrate resistance: treatment options
People with nonmetastatic castrate resistant prostate cancer can choose from the following treatment options. According to your age, health condition, and other factors, your doctor or healthcare team will suggest ideal treatment plans
Hormone therapy
The use of hormone therapy can be one way of managing this cancer if your PSA level is increasing, even if you do not show any signs or symptoms of prostate cancer. By using hormone therapy, certain hormones will be altered or blocked in order to stop the spread of cancerous cells and to slow down the growth of those cells as long as possible. It is expected that doctors will also suggest effective medicines such as Indenza in addition to the hormone therapy you are currently receiving to treat CRPC. A combination of chemotherapy and hormone therapy can provide the best results.
Chemotherapy
The most effective method for treating castrate-resistant prostate cancer is chemotherapy. Cancerous cells are destroyed through chemotherapy management using anticancer drugs.
Targeted therapy
Targeted therapy includes medications such as Indenza 40 mg that target particular molecules or proteins in cancerous cells to stop the spread and growth of cancer to limit damage to normal cells. Most targeted drug therapy is used to treat metastatic castrate-resistant prostate cancer.
Radiation therapy
Cancer cells are destroyed, urinary problems caused by tumors are relieved, and pain from cancer spread to bones is relieved. In radiation therapy, cancerous cells are destroyed with high-energy particles or rays.
Bone-targeted therapy
Most individuals with metastatic castrate-resistant prostate cancer develop bone metastasis, when cancer spreads through the bones. There is also a high risk of developing pathological fractures, skeletal complications, spinal cord compression, etcetera, as well as other complications. In the treatment of bone metastasis, the most common options are the use of bisphosphonates, such as zoledronic acid, corticosteroids such as dexamethasone and prednisone, pain medications, kyphoplasty, systematic radiation therapy, and external radiation therapy.
Clinical trials
The best way to manage prostate cancer is to consult your healthcare provider if you would like to know more about clinical trials. In the field of cancer treatment and prevention, clinical trials have been recognized as an innovative and new method. In addition to clinical trials, you must regularly perform imaging tests and phase tests in order to be able to determine if the prostate cancer has spread or grown to other parts of the body. Castrate resistant prostate cancer can be effectively treated with the help of effective medicine like Enzalutamide. Your healthcare provider will be able to tell you how much enzalutamide will cost and the right dose or strength that you should take.
Conclusion
All of the above methods are the best management techniques for metastatic castrate-resistant prostate cancer, as they help slow the growth and spread of cancer cells, improve quality of life, increase life expectancy, and relieve castrate-resistant prostate cancer symptoms. Since CRPC is considered a fatal and incurable illness, early diagnosis and treatment options would be helpful in improving the prognosis for people with CRPC. In addition to these treatments and methods of management, there are several more that are currently being investigated and researched, and that will soon add to the therapeutic options and will soon be available to patients as well.
